1498 related articles for article (PubMed ID: 34019806)
21. Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma.
Zhu Z; Li G; Li Z; Wu Y; Yang Y; Wang M; Zhang H; Qu H; Song Z; He Y
Front Immunol; 2022; 13():914612. PubMed ID: 36072600
[TBL] [Abstract][Full Text] [Related]
22. Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy.
Xie F; Zhang J; Wang J; Reuben A; Xu W; Yi X; Varn FS; Ye Y; Cheng J; Yu M; Wang Y; Liu Y; Xie M; Du P; Ma K; Ma X; Zhou P; Yang S; Chen Y; Wang G; Xia X; Liao Z; Heymach JV; Wistuba II; Futreal PA; Ye K; Cheng C; Xia T
Clin Cancer Res; 2020 Jun; 26(12):2908-2920. PubMed ID: 31911545
[TBL] [Abstract][Full Text] [Related]
23. Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance.
Galbo PM; Zang X; Zheng D
Clin Cancer Res; 2021 May; 27(9):2636-2647. PubMed ID: 33622705
[TBL] [Abstract][Full Text] [Related]
24. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
25. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
26. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment.
Sun D; Wang J; Han Y; Dong X; Ge J; Zheng R; Shi X; Wang B; Li Z; Ren P; Sun L; Yan Y; Zhang P; Zhang F; Li T; Wang C
Nucleic Acids Res; 2021 Jan; 49(D1):D1420-D1430. PubMed ID: 33179754
[TBL] [Abstract][Full Text] [Related]
27. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
28. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Qiu H; Shao Z; Wen X; Jiang J; Ma Q; Wang Y; Huang L; Ding X; Zhang L
Front Immunol; 2021; 12():716710. PubMed ID: 34539652
[TBL] [Abstract][Full Text] [Related]
29. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
30. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
31. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
[TBL] [Abstract][Full Text] [Related]
32. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
Cao R; Yuan L; Ma B; Wang G; Tian Y
Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
[TBL] [Abstract][Full Text] [Related]
33. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
Osipov A; Saung MT; Zheng L; Murphy AG
J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
[TBL] [Abstract][Full Text] [Related]
34. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
[TBL] [Abstract][Full Text] [Related]
35. Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling.
Chen PY; Wei WF; Wu HZ; Fan LS; Wang W
Front Immunol; 2021; 12():671595. PubMed ID: 34305902
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in understanding the immune microenvironment in ovarian cancer.
Chen J; Yang L; Ma Y; Zhang Y
Front Immunol; 2024; 15():1412328. PubMed ID: 38903506
[TBL] [Abstract][Full Text] [Related]
37. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
[TBL] [Abstract][Full Text] [Related]
38. Remodeling the fibrotic tumor microenvironment of desmoplastic melanoma to facilitate vaccine immunotherapy.
Zhu H; Liu Q; Miao L; Musetti S; Huo M; Huang L
Nanoscale; 2020 Feb; 12(5):3400-3410. PubMed ID: 31989142
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
40. Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients.
Wang P; Li J; Wu M; Ye M; Huang K; Zhu X
Front Immunol; 2021; 12():722479. PubMed ID: 34566979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
